EXTON, Pa., Nov. 7 /Xinhua-PRNewswire/ -- Melior Discovery, Inc.
announced today that it has signed a research collaboration with Merck & Co.,
Inc. to evaluate the activity of select Merck neuroscience compounds
utilizing elements of Melior’s in vivo Indication Discovery platform.
Under the terms of the agreement Merck will pay undisclosed fees for
priority access to aspects of Melior’s exclusively licensed platform.
“Our agreement represents a significant opportunity for both Merck and
Melior,” said Andrew Reaume, Ph.D., President and CEO of Melior. “Merck is
gaining access to a unique in vivo testing platform and this agreement
validates Melior’s Indication Discovery platform capabilities. We look
forward to a productive collaboration.”
Melior Discovery Overview
Melior Discovery is leading the transformation of pharmaceutical drug
repositioning with its unique Indication Discovery platform of multiplexed in
vivo models. It is using this capability to both build an internal pipeline
of development candidates as well as sharing this capability with pharma and
biotechnology company partners. In the former case, the Company is
identifying “privileged” compounds that have been discontinued by others
which it identifies through a close working relationship with Dr. Christopher
Lipinski. In its partnered arrangements, Melior offers pharmaceutical
partners an effective approach to expand their late-stage pipelines with
safe, high-quality drug candidates that originated from internal R&D efforts.
Melior Discovery is located in Exton, PA.
